The effect of bitter melon (Mormordica charantia) in patients with diabetes mellitus: A systematic review and meta-analysis

Nutrition and Diabetes

Volumn 4, Issue 12, 2014, Pages

  Yin, R V ^a   Lee, N C ^a   Hirpara, H ^a   Phung, O J ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

DIABETIC PATIENT; DIET SUPPLEMENTATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; MOMORDICA CHARANTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84927767178     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.42     Document Type: Review

References (18)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
2. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32: S151-S156.
3. National Diabetes Information Clearinghouse (NDIC). National Diabetes Statistics 2011, http://diabetes.niddk.nih.gov/dm/pubs/statistics/#fast. Accessed July 2013.
4. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on anti-diabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed 2012; 2: 320-330.
5. Basch E, Garbardi S, Ulbricht C. Bitter melon (Momordica charantia): A review of efficacy and safety. Am J Health-Syst Pharm 2003; 60: 356-359.
6. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
8. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-773.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
10. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
11. Dans AML, Villarruz MVC, Jimeno CA, Javelosa MAU, Chua J, Bautista R et al. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 2007; 60: 554-559.
12. Zanker KS, Mang B, Wolters M, Hahn A. Personalized diabetes and cancer medicine: a rationale for anti-diabetic nutrition (bitter melon) in a supportive setting. Curr Cancer Ther Rev 2012; 8: 66-77.
13. John AJ, Cherian R, Subhash HS, Cherian AM. Evaluation of the efficacy of bitter gourd (Momordica charantia) as an oral hypoglycemic agents-a randomized controlled clinical trial. Indian J Physiol Pharmacol 2003; 47: 363-365.
14. Lim ST, Jimeno CA, Razon-Gonzales EB, Velasquiz EN. The MOCHA DM study: the effect of Momordica charantia tablets on glucose and insulin levels during the post prandial state among patients with type 2 diabetes mellitus. Phillipine J Int Med 2010; 48: 19-25.
15. Sacks DB. Measurement of hemoglobin A1c. Diabetes Care 2012; 35: 2674-2680.
16. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic Review of Herbs and Dietary Supplements for glycemic control in diabetes. Diabetes Care 2003; 26: 1277-1294.
17. Fuangchan A, Sonthisombat P, Seubnekarn T, Chanouan R, Chotchaisuwat P, Sirigulsatein V et al. Hypoeglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol 2011; 134: 422-428.
18. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr 2009; 102: 1703-1708.